Emergence - Emergence

Drug repurposing for nonsense-mediated Cystic Fibrosis and Hemophilia – REP-4-nmCF

Submission summary

Rep-4-nmCF is the continuation of a drug repurposing programme started 2 years ago by the investigators. It is set to enable the clinical development of an old drug in nonsense mediated genetic diseases. By screening a library of 1200 marketed drugs on a cell model of nonsense mutation defect, they have discovered that amlexanox, a drug used for asthma in Japan, can correct the phenotype of cells from patients having nonsense mediated cystic fibrosis. This project will confirm these results on epithelia from more patients in cystic fibrosis, and pinpoint the molecular determinants of the mode-of-action of amlexanox in nonsense mutation cells.
All together, materials and data produced by this project will support the scientific rational for a clinical trial, confirm the initial choice of cystic fibrosis and hemophilia, and improve the positions of the consortium in future negotiations with the holder of the current market authorization for the oral form of amlexanox.

Project coordinator

Monsieur Benoit Deprez (Unité Biostructures et découverte de médicaments) – benoit.deprez@univ-lille2.fr

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

Inserm U761 Unité Biostructures et découverte de médicaments
AVENIR LEJEUNE Equipe Avenir - Etude de la régulation du mécanisme de nonsense-mediated mRNA decay (NMD)
SATT NdFV SATT Nord de France Valo SAS

Help of the ANR 252,259 euros
Beginning and duration of the scientific project: September 2012 - 18 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter